Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Shares Outstanding (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Shares Outstanding for 11 consecutive years, with $59.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 7.89% to $59.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.0 million through Dec 2025, up 7.89% year-over-year, with the annual reading at $59.0 million for FY2025, 7.89% up from the prior year.
  • Shares Outstanding hit $59.0 million in Q4 2025 for Voyager Therapeutics, up from $55.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $59.0 million in Q4 2025 to a low of $37.6 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $46.2 million across 5 years, with a median of $43.8 million in 2023.
  • Biggest five-year swings in Shares Outstanding: increased 1.39% in 2021 and later rose 25.05% in 2024.
  • Year by year, Shares Outstanding stood at $37.9 million in 2021, then increased by 1.83% to $38.6 million in 2022, then increased by 14.05% to $44.0 million in 2023, then increased by 24.28% to $54.7 million in 2024, then rose by 7.89% to $59.0 million in 2025.
  • Business Quant data shows Shares Outstanding for VYGR at $59.0 million in Q4 2025, $55.5 million in Q3 2025, and $55.4 million in Q2 2025.